DV
Dividend Vision

EGRX — Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc (EGRX)

Total return is -95.4% over the past 12.5 years, 521.7 points behind SPY at 426.3%. Its deepest 1-year drawdown was 100.0%.

Eagle Pharmaceuticals is a pharmaceutical company focused on developing and commercializing medications for central nervous system disorders, metabolic critical care, and oncology, with marketed products including RYANODEX for malignant hyperthermia, BELRAPZO and BENDEKA for certain lymphomas, PEMFEXY for lung cancer and mesothelioma, and several other FDA-approved therapies. The company does not currently distribute dividends. Eagle Pharmaceuticals appeals primarily to growth-oriented investors seeking exposure to the pharmaceutical sector, as the company is focused on developing and expanding its product pipeline rather than generating current income.

EGRX key facts

Asset type
Stock
Asset class
Equity
Inception date
02/12/2014
Last close
$0.59
Market cap
$3,289,388
Average volume
0.0
Beta
0.628
Payout ratio
0.0
P/E ratio
1.5625
Forward P/E
11.3379
EPS
$0.16